Dapagliflozin and Right Heart Recovery After ASD Device Closure
NCT : NCT07823972 · NOT_YET_RECRUITING
Publicité
Résumé succinct
The aim of this study is to evaluate the clinical and echocardiographic influence of dapagliflozin on right ventricular reverse remodeling in adult patients following successful transcatheter Atrial Septal Defect (ASD) device closure.
Source officielle
Voir sur ClinicalTrials.gov →Données issues de l’API ClinicalTrials.gov. Pour connaître le statut le plus récent, consultez la fiche officielle.